Release date: 2010-11-01 Source: Shanghai Medical Device Industry Association website Accelerate Freeze Dried Fig is made of selected ripe figs. The international advanced ultra-low temperature FD technology is adopted to sublime the water content of fruit, without changing the fruit color, shape and flavor. Retaining the original nutritional and medicinal components, without any additive, pigment, sweetener or preservative, it is the best-quality dried fruit. Accelerate Dried Fig won the Silver Medal at the [2017 China Characteristic Tourist Commodity Contest", as well as the [Gold Medal" of [Lishang Weihai" Most Characteristic Tourist Commodity. Freeze Dried Fig Fig WEIHAI ACCELERATE BIOTECHNOLOGY CO, LTD , https://www.accelerfig.com
In October 2010, the first clinical trial of Tubridge dense mesh stent, which was developed by Shanghai Changhai Hospital and Shanghai Weichuang Medical Device Co., Ltd., with its own independent intellectual property rights, officially passed the China Food and Drug Administration. Approved and certified by the relevant ethics committee, and began clinical trials at Changhai Hospital affiliated to the Second Military Medical University. The successful development of the device marks that China has reached the international advanced level in the field of neurological intervention product research and development, and will greatly reduce the cost of treatment of various intracranial aneurysms in China. It is estimated that if the product is put into production, it is expected to reduce the cost of treatment of intracranial aneurysms by more than 60%.
According to experts, intracranial aneurysms are one of the serious threats to human health. In the event of a rupture, the mortality rate of the first bleeding is above 30%. In the past, the treatment of intracranial aneurysms was mainly craniotomy. In the past 20 years, minimally invasive interventional procedures have gradually become one of the preferred treatments for intracranial aneurysms. However, simple interventional embolization can not treat all intracranial aneurysms, and the recurrence rate after embolization is high. In addition, the cost of treatment is high, and it is difficult to be widely used in China. The Cerebrovascular Disease Treatment Research Group led by Professor Liu Jianmin of the Department of Neurosurgery at Changhai Hospital has always focused on minimally invasive interventional therapies for complex intracranial aneurysms. Since the successful implementation of the first intracranial stenting in China in 2000, they have conducted in-depth research from the aspects of the occurrence, development, rupture and recurrence of intracranial aneurysms. From the design improvement of the stent to the hemodynamic study in the stent, from the material selection of the stent to the influence of the stent on the vascular endothelial function, from the determination of the mesh density of the stent to the computer simulation of blood flow data, the research team of the Changhai Hospital cerebrovascular disease gradually A new strategy for the treatment of intracranial aneurysms is to transform the traditional intratumoral tamponade into reconstruction and repair treatment for diseased vessels.
The research and development of this device has been funded by the National Natural Science Foundation of China, the Shanghai Municipal Science and Technology Commission key project, and the military high-tech major projects. It is a successful example of the transformation of clinical research into a scientific research industry in China.